Han et al. compared gefitinib treatment in both sensitive and resistant lung cancer cell lines; interestingly, immunoblotting and immunofluorescent staining demonstrated an increase in both ATG5 and ATG7 levels and LC3II expression in resistant cell lines [74]. This evidence concerns the gene ATG7 and lung carcinoma.